Policy Developments - The State Council approved the revised draft of the Drug Administration Law Implementation Regulations, emphasizing the importance of timely revisions to drug management laws for ensuring public safety and promoting the healthy development of the pharmaceutical industry [1] Industry Initiatives - Hainan Province aims to develop over six distinctive traditional Chinese medicine health tourism routes by the end of 2028, with a target of cultivating over 1 million mu of medicinal herb planting and breeding areas, and achieving a 15% growth in the overall output value of traditional Chinese medicine [2] Drug and Medical Device Approvals - Xingqi Eye Medicine announced the approval of its atropine sulfate eye drops for children aged 6 to 12, with new product specifications added [1] Capital Market Activities - Sinovac Biotech has repurchased approximately 1.32 million shares, accounting for 0.66% of its total share capital, with a total expenditure of approximately RMB 49.24 million [3] - Dongcheng Pharmaceutical plans to repurchase shares worth between RMB 100 million and RMB 200 million for employee stock ownership plans, with a maximum repurchase price of RMB 18.00 per share [4] - Haizheng Pharmaceutical's major shareholder intends to transfer 6.06% of the company's shares through a public solicitation, pending approval from relevant authorities [5] Strategic Collaborations - Sinopharm Holdings and Betta Pharmaceuticals have signed a strategic cooperation agreement to enhance collaboration and create a new efficient pharmaceutical supply chain ecosystem [6] Personnel Changes - The independent director of Nanxin Pharmaceutical, Shen Yunqiao, has resigned for personal reasons, and will continue to fulfill his duties until a new independent director is elected [7]

Investment Agreements - Longpan Technology plans to invest 2 billion yuan to establish a high-performance lithium battery cathode material project [2] - Yanjing Co. intends to acquire control of high-frequency carrier board manufacturer Yongqiang Technology, with stock suspension [2] - Zhongjian Technology has approved a project for the collaborative development of intelligent robots [2] - Mengwang Technology signed a cooperation agreement worth 60 million yuan with Shenzhou Liuhe for the R&D and production of heavy-lift drones [3] - Jiu Ding New Materials plans to invest 246 million yuan to build a large-scale wind turbine blade production line [4] - Jincai Hulin intends to acquire 51% of Wuxi Sanli for 63.43 million yuan [5] - Changyuan Power plans to invest in a 100MW wind farm project in Hubei Province with a total investment of 562 million yuan [7] - Shengyang Co. plans to acquire 51% of Shenzhen Daren High-Tech for 74.47 million yuan [8] Shareholding Changes - *ST Zhongzhuang announced a change in actual control to Long Jisheng due to the execution of a restructuring plan [9] - Hunan Baiyin's major shareholder reduced its stake to below 5% [10] Stock Buybacks - Century Huatong plans to repurchase shares worth between 300 million and 600 million yuan [11] - Dongcheng Pharmaceutical intends to repurchase shares for 100 million to 200 million yuan [12] - Ningde Times has repurchased a total of 15.99 million A-shares for 4.386 billion yuan [13] Business Operations and Performance - Bailong Oriental expects a net profit increase of 46.34% to 70.73% in 2025 [13] - Longjian Co. anticipates a net profit of 405 million yuan in 2025, a decrease of 2.05% [13] - BYD reported cumulative sales of 4.602 million new energy vehicles in 2025, a 7.73% increase year-on-year [14] Financing and Capital Increases - Zhenhua Co. plans to issue convertible bonds to raise no more than 878 million yuan for projects [15] - Huashu Holdings intends to raise up to 600 million yuan through a private placement to Hongtai Group [15] Other Developments - Xinxing Chemical has resumed production of biomass cellulose filament products after equipment upgrades [24] - Guoguang Electric announced the resumption of the general manager's duties after the lifting of restrictions [25]

Core Viewpoint - The approval of two new specifications of atropine sulfate eye drops by the National Medical Products Administration represents a significant expansion of the company's product matrix for myopia prevention, which is expected to drive further growth in its performance [1][2]. Group 1: Product Approval and Specifications - The company received approval for two new specifications of atropine sulfate eye drops: 0.02% (0.4ml: 0.08mg) and 0.04% (0.4ml: 0.16mg) [1]. - The previously approved 0.01% (0.4ml: 0.04mg) specification is the first eye drop product approved in China for myopia-related indications [2]. - The new products are based on existing formulations and are expected to enhance the company's offerings in the myopia prevention market [2]. Group 2: Financial Performance - The company has experienced rapid growth in recent years, with a 32.42% increase in revenue and a 40.84% increase in net profit attributable to shareholders in 2024 compared to 2023 [2]. - In the first three quarters of the current year, the company's revenue grew by 32.27%, while net profit surged by 105.98% [2]. Group 3: Market Context and Future Outlook - The increasing prevalence of myopia, particularly among children and adolescents, presents a significant public health challenge and a large market opportunity for myopia prevention products [3]. - The introduction of the new products is expected to optimize the company's product matrix for myopia prevention, providing more options for patients and potentially enhancing the company's growth [3]. - The company is actively exploring different mechanisms for myopia prevention based on foundational research, indicating a commitment to expanding its product offerings in this area [3].

Core Viewpoint - Xingqi Eye Pharmaceutical has received approval from the National Medical Products Administration for the supplementary application of atropine sulfate eye drops, expanding its product specifications to include 0.02% and 0.04% concentrations, which are currently not available in the domestic market [1][2] Group 1: Product Development - The new product specifications of 0.02% (0.4ml: 0.08mg) and 0.04% (0.4ml: 0.16mg) will enhance the company's product matrix, addressing the unmet needs in myopia treatment for children and adolescents [1][2] - The company has a comprehensive product line that includes treatments for myopia progression, dry eye, infections, inflammation, and glaucoma, establishing a robust portfolio in ophthalmic medications [1] Group 2: Financial Performance - For the first three quarters of 2025, the company reported a revenue of 1.904 billion yuan, reflecting a year-on-year growth of 32.27%, driven by core products like atropine [2] - The approval of the new formulations is expected to further boost the company's sales performance and market presence in the ophthalmic sector [2] Group 3: Strategic Initiatives - The company aims to enhance product accessibility and patient experience through innovative drug pipelines, differentiated product strategies, and academic promotion in the field of myopia prevention [2] - Industry experts believe that the approval of the new formulations will facilitate continuous product iteration and better meet the treatment needs for myopia in young patients [2]

Group 1 - Zhongmin Resources has completed the construction of a 30,000-ton high-purity lithium salt project, which began trial production on January 2, 2026, with a total investment of 121 million yuan [2] - Shaoyang Hydraulic's acquisition of 100% of Chongqing Xincheng Hangrui Technology has been accepted by the Shenzhen Stock Exchange [3] - Xingqi Eye Medicine received approval for the supplementary application of atropine sulfate eye drops, aimed at delaying myopia progression in children aged 6 to 12 [4] Group 2 - Bailong Oriental expects a net profit of 600 million to 700 million yuan for 2025, representing a year-on-year increase of 46.34% to 70.73% [5] - Magmite's application for a private placement has been approved by the China Securities Regulatory Commission [6] - *ST Aowei's stock may face delisting risk due to a market capitalization below 500 million yuan [7] Group 3 - Changyuan Power plans to invest 572 million yuan in a wind power project in Hubei Province, with a planned capacity of 100 MW [8] - Haizheng Pharmaceutical's shareholder intends to transfer 6.06% of the company's shares [9] - Fusheng Technology has received approval for a share issuance to acquire assets and raise matching funds [10] Group 4 - Tenglong Co. plans to establish a joint venture for a liquid cooling company with an investment of 30 million yuan [11] - *ST Tianshan reported sales of live livestock amounting to 24.6 million yuan in December 2025, with significant year-on-year growth [12] - Hengxin Oriental's controlling shareholder has released a pledge of 0.91% of shares [13] Group 5 - Peking University Pharmaceutical plans to distribute a cash dividend of 1.68 yuan per 10 shares, totaling 100 million yuan [14] - Tianlong Co. intends to acquire a 54.87% stake in Suzhou Haomi Bo for 232 million yuan [15] - Jinggong Technology's first carbon fiber production line has successfully commenced trial production [16] Group 6 - Shanfeng Cement has terminated its investment and asset acquisition plans due to disagreements on asset valuation [17] - Shengyang Co. plans to acquire 51% of Shenzhen Daren High-tech for approximately 74.47 million yuan [18] - Xinxiang Chemical has resumed production of biomass cellulose filament after equipment upgrades [19] Group 7 - Jiuding New Materials plans to invest 246 million yuan in a wind turbine blade production line project [20] - Hunan Baiyin's shareholder has reduced its stake to below 5% [21] - Century Huatong intends to repurchase shares worth 300 million to 600 million yuan [22] Group 8 - Jincai Hulin plans to acquire 51% of Wuxi Sanli for 63.43 million yuan [23] - Jiamei Packaging's stock has experienced abnormal trading fluctuations, but no significant undisclosed information has been found [25] - Guoguang Electric's general manager has resumed duties after the lifting of restrictions [26] Group 9 - Shengxing Co. is planning a private placement for 2025, with no significant changes in its operational situation [27] - *ST Meigu has applied to lift the delisting risk warning after completing its restructuring plan [28] - CATL has repurchased 15.99 million A-shares for a total of 4.386 billion yuan [29] Group 10 - Phoenix Shipping's actual controller has been released from mandatory measures [30] - Guoxin Technology's new neural network processor has successfully passed internal testing [31] - Yanjing Co. plans to acquire control of Ningbo Yongqiang Technology, leading to a stock suspension [32]

格隆汇1月4日丨兴齐眼药(300573.SZ)公布，收到国家药品监督管理局核准签发的硫酸阿托品滴眼液 《药品补充申请批准通知书》。公司硫酸阿托品滴眼液的研发代码为SQ-729，适应症为：本品用于延 缓球镜度数为-1.00D至-4.00D（散光≤1.50D、屈光参差≤1.50D）的6至12岁儿童的近视进展。本次补充 申请是在我公司已上市硫酸阿托品滴眼液（国药准字H20243320）基础上增加两个产品规格（1） 0.02%（0.4ml：0.08mg）、（2）0.04%（0.4ml：0.16mg）。本次补充申请开展了一项关于0.02%和 0.04%阿托品滴眼液的Ⅲ期临床研究，本研究采用多中心、随机、双盲、安慰剂平行对照、优效性设计 的试验方法。研究方案中关键指标、给药周期、停药后观察期设定均参照国家药品监督管理机构最新发 布的《控制近视进展药物临床研究技术指导原则（2020年12月）》，共随机入组800例，给药期2年，停 药观察期1年，研究结果显示，0.02%和0.04%阿托品滴眼液与安慰剂相比，均能够有效延缓儿童近视进 展，且总体安全性良好。截止目前，国内外尚无0.02%和0.04%硫酸阿托品滴眼液近视相关适应症 ...

北京商报讯（记者 丁宁）1月4日晚间，兴齐眼药（300573）发布公告称，公司收到国家药品监督管理 局核准签发的硫酸阿托品滴眼液《药品补充申请批准通知书》。 公告显示，公司硫酸阿托品滴眼液的适应症为用于延缓球镜度数为-1.00D至-4.00D（散光≤1.50D、屈光 参差≤1.50D）的6至12岁儿童的近视进展。本次补充申请是在公司已上市硫酸阿托品滴眼液基础上增加 两个产品规格0.02%（0.4ml：0.08mg）、0.04%（0.4ml：0.16mg）。 截至目前，国内外尚无0.02%和0.04%硫酸阿托品滴眼液近视相关适应症产品获批上市。国外已有同类 0.01%、0.025%硫酸阿托品滴眼液产品上市。 ...

Core Viewpoint - The announcement highlights the approval of a new low-concentration atropine eye drop by the National Medical Products Administration, which is expected to uniquely position the company in the market for myopia treatment in children aged 6-12 [1] Group 1: Product Approval - The company received approval for supplementary applications of atropine sulfate eye drops in two new concentrations: 0.02% and 0.04% [1] - The approval numbers are H20258301 and H20258302, with a validity period until March 2029 [1] Group 2: Market Position - This product is the first of its kind in China aimed at delaying the progression of myopia in children with a spherical equivalent of -1.00D to -4.00D [1] - Phase III clinical trials demonstrated that both concentrations significantly delayed myopia progression compared to a placebo, with good safety profiles [1] - Currently, there are no competing products with the same concentrations available in the domestic or international markets, indicating a potential monopoly in this niche [1]

每经AI快讯，1月4日，兴齐眼药(300573.SZ)公告称，公司收到国家药品监督管理局核准签发的硫酸阿 托品滴眼液《药品补充申请批准通知书》。该药品适用于延缓球镜度数为-1.00D至-4.00D（散光 ≤1.50D、屈光参差≤1.50D）的6至12岁儿童的近视进展。公司在已上市硫酸阿托品滴眼液基础上增加两 个产品规格，分别为0.02%（0.4ml：0.08mg）和0.04%（0.4ml：0.16mg）。研究结果显示，0.02%和 0.04%阿托品滴眼液与安慰剂相比，均能有效延缓儿童近视进展，且总体安全性良好。由于医药产品市 场销售情况可能受多种因素影响，存在不确定性，敬请投资者谨慎决策，注意投资风险。 （文章来源：每日经济新闻） ...

兴齐眼药1月4日公告，公司收到国家药品监督管理局核准签发的硫酸阿托品滴眼液《药品补充申请批准 通知书》。该药品的适应症为：本品用于延缓球镜度数为-1.00D至-4.00D（ 散光 ≤1.50 D 、 屈光参差 ≤1.50 D ）的6至12岁儿童的近视进展。本次补充申请是在公司已上市硫酸阿托品滴眼液基础上增加两 个产品规格（1）0.02%（0.4ml:0.08mg）、（2）0.04%（0.4ml:0.16mg）。 ...